This finding which was subsequently explored by Frank's group who showed co-immunoprecipitation of these two receptors in breast cancer T47D and prostate cancer LNCaP cells, and the ability of human GH to signal through the resulting heterodimer because hGH can bind to both site 1 and site 2 of the prolactin receptor [46]. The gene discussed is GH1; the disease is breast cancer.